Abstract

Papillary renal cell carcinoma (pRCC) is the most heterogenous renal cell carcinoma. Patient survival varies and no effective therapies for advanced pRCC exist. Histological and molecular characterization studies have highlighted the heterogeneity of pRCC tumours. Recent studies identified the proximal tubule (PT) cell as a cell-of-origin for pRCC. However, it remains elusive whether other pRCC subtypes have different cell-of-origin. Here, by obtaining genome-wide chromatin accessibility profiles of normal human kidney cells using single-cell transposase-accessible chromatin-sequencing and comparing the profiles with pRCC samples, we discover that besides PT cells, pRCC can also originate from kidney collecting duct principal cells. We show pRCCs with different cell-of-origin exhibit different molecular characteristics and clinical behaviors. Further, metabolic reprogramming appears to mediate the progression of pRCC to the advanced state. Here, our results suggest that determining cell-of-origin and monitoring origin-dependent metabolism could potentially be useful for early diagnosis and treatment of pRCC.

The heterogeneity of cell-of-origin for papillary renal cell carcinoma (pRCC) remains unknown. Here, with single-cell ATAC-seq from normal human kidney cells and ATACseq profiles from pRCC samples, the authors show that pRCC can originate from kidney collecting duct principal cells and this subtype is associated with advanced pRCC.

Details

Title
Single-cell chromatin accessibility landscape in kidney identifies additional cell-of-origin in heterogenous papillary renal cell carcinoma
Author
Wang, Qi 1 ; Zhang, Yang 2 ; Zhang Bolei 3 ; Fu, Yao 4   VIAFID ORCID Logo  ; Zhao Xiaozhi 5 ; Zhang, Jing 1 ; Zuo Ke 6 ; Xing Yuexian 6 ; Jiang, Song 6   VIAFID ORCID Logo  ; Qin Zhaohui 7   VIAFID ORCID Logo  ; Li Erguang 1 ; Guo Hongqian 5   VIAFID ORCID Logo  ; Liu, Zhihong 2   VIAFID ORCID Logo  ; Yang, Jingping 8   VIAFID ORCID Logo 

 Medical School of Nanjing University, Nanjing, China (GRID:grid.41156.37) (ISNI:0000 0001 2314 964X) 
 Medical School of Nanjing University, Nanjing, China (GRID:grid.41156.37) (ISNI:0000 0001 2314 964X); Medical School of Nanjing University, National Clinical Research Center for Kidney Disease, Jinling Hospital, Nanjing, China (GRID:grid.41156.37) (ISNI:0000 0001 2314 964X) 
 School of Computer Science, Nanjing University of Posts and Telecommunications, Nanjing, China (GRID:grid.453246.2) (ISNI:0000 0004 0369 3615) 
 Medical School of Nanjing University, Department of Pathology, Affiliated Drum Tower Hospital, Nanjing, China (GRID:grid.41156.37) (ISNI:0000 0001 2314 964X) 
 Medical School of Nanjing University, Department of Urology, Affiliated Drum Tower Hospital, Nanjing, China (GRID:grid.41156.37) (ISNI:0000 0001 2314 964X) 
 Medical School of Nanjing University, National Clinical Research Center for Kidney Disease, Jinling Hospital, Nanjing, China (GRID:grid.41156.37) (ISNI:0000 0001 2314 964X) 
 Emory University, Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502) 
 Medical School of Nanjing University, Nanjing, China (GRID:grid.41156.37) (ISNI:0000 0001 2314 964X); Medical School of Nanjing University, National Clinical Research Center for Kidney Disease, Jinling Hospital, Nanjing, China (GRID:grid.41156.37) (ISNI:0000 0001 2314 964X); Nanjing University, Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing, China (GRID:grid.41156.37) (ISNI:0000 0001 2314 964X) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2619578453
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.